ZL0580

Modify Date: 2024-01-10 20:29:35

ZL0580 Structure
ZL0580 structure
Common Name ZL0580
CAS Number 2377151-10-3 Molecular Weight 532.53
Density N/A Boiling Point N/A
Molecular Formula C25H23F3N4O4S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of ZL0580


ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter[1][2][3].

 Names

Name ZL0580

 ZL0580 Biological Activity

Description ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter[1][2][3].
Related Catalog
Target

BRD4 (BD1)

In Vitro ZL0580 (8 μM, 2 days, PBMCs of viremic HIV-infected individuals) induces HIV transcriptional suppression with low toxicity[1]. ZL0580 treatment (10 μM) suppresses both PMA-stimulated and basal HIV transcription[1]. Cell Viability Assay[1] Cell Line: HIV-infected human CD4+ T cells. Concentration: 0-8 μM. Incubation Time: 2 days. Result: Suppress HIV in primary CD4+ T cell. Single treatment (8 μM) led to almost completed loss of productive HIV infection in CD4+ T cells. RT-PCR[1] Cell Line: PBMCs of viremic HIV-infected individuals. Concentration: 8 μM. Incubation Time: 2 days. Result: Suppresses HIV transcription ex vivo in PBMCs of viremic HIV-infected individuals. Cell Cytotoxicity Assay[1] Cell Line: J-Lat cells. Concentration: 0-80 μM. Incubation Time: 1 and 3 days. Result: Did not cause significant cell death at concentrations below 40 μM. Treatment of J-Lat cells with ZL0580 (10 μM) also did not cause significant cell death on days 2, 7, and 14 compared with NC in both PMA-activated and unstimulated cells.
References

[1]. Niu Q, et al. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J Clin Invest. 2019 Jul 22;129(8):3361-3373.

[2]. Vansant G, et al. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12(1). pii: E84.

[3]. Brasier AR, et al. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discov Today. 2020 Jan;25(1):126-132.

 Chemical & Physical Properties

Molecular Formula C25H23F3N4O4S
Molecular Weight 532.53